Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 1

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 1
---
5, or Proposal No. 6, “the “Adjournment 
 Proposal” or “Proposal No. 7”).                                                                                                        |

Please refer to the attached proxy statement for further information with respect to the business to be transacted at the Telomir Annual Meeting.

Telomir and TELI Pharmaceuticals, Inc., a private company incorporated under the laws of Delaware (“TELI”) have entered into an Agreement and Plan of Merger and Reorganization, dated November 20, 2025 (the “Merger Agreement”), pursuant to which a wholly owned subsidiary of Telomir will merge with and into TELI, with TELI surviving as a wholly owned subsidiary of Telomir (the “Merger”).

At the effective time of the Merger (the “Effective Time”), each outstanding share of common stock of TELI, $0.0001 par value per share (“TELI Common Stock”), will be converted into the right to receive such number of Telomir Common Stock as is calculated based on the exchange ratio of the shares for the Merger (the “Exchange Ratio”). The Exchange Ratio is calculated using the relative company valuations of each of TELO and TELI, as determined by Moore (as further described herein). It is expected that shareholders of TELO will receive one share of TELI Common Stock for each share of TELI Common Stock held (the “Merger Share Consideration”). The TELI Common Stock issued as the consideration will not be registered for trading under the Securities Act.

In addition
to the Merger Consideration, Erez Aminov and Bayshore Trust, shareholders of TELI, hold 4,250,000 and 10,000,000 warrants,
respectively, to purchase TELI Common Stock (the “Warrants”). The Warrants are exercisable upon FDA acceptance of an
Investigational New Drug (IND) application for Telomir- at $2.00 per share, for a period of 10 years. At Closing, the Warrants will
be converted to warrants to purchase Telomir Common Stock at similar terms as the Warrants.

Immediately after the Merger, the pre-Merger equity holders of Telomir are expected to hold approximately 50% of the outstanding shares of Telomir, on a non-diluted basis, and the pre-Merger equity holders of TELI are expected to hold approximately 50% of the outstanding shares of Telom